Pfizer secures up to $1.5B to test a monthly GLP-1 shot
Pfizer has secured up to $1.5B from Blackstone Life Sciences for developing its experimental obesity drug, berobenatide, through 2028. The funding will support 10 Phase 3 trials for weight management and related conditions. Pfizer reported encouraging Phase 2b results, with up to 12.3% average weight loss after switching from weekly to monthly injections. Blackstone could receive milestone payments tied to U.S. approval and sales targets.
How this was made

The 30-second read
Why it matters
The partnership with Blackstone provides up to $1.5 billion, reducing cash outlay and signaling confidence, which may lift PFE stock.
Market read
First disclosure of a major funding deal for a potential monthly obesity therapy, a material catalyst for Pfizer.
What to watch
Regulatory timeline and reimbursement uncertainty for a monthly GLP‑1 could delay commercial benefits.
Background
Pfizer is expanding its GLP‑1 portfolio beyond weekly injections, aiming for a more convenient monthly regimen.
Ticker impact
Pfizer secured up to $1.5 billion from Blackstone Life Sciences to fund Phase 3 trials of its monthly GLP‑1 obesity drug berobenatide.
likely modest upside as investors price in reduced cash‑burn and upside potential of a differentiated monthly obesity therapy.
Large non‑dilutive capital injection and progress toward a first‑in‑class monthly GLP‑1 could improve long‑term revenue outlook.
Market effects
May boost the obesity‑treatment segment and increase competitive pressure on Novo Nordisk and Eli Lilly.
U.S. biotech sector could see modest gains as a major player advances a novel dosing regimen.
Potentially influences global obesity‑drug pipelines and investor sentiment toward GLP‑1 therapeutics.
Counterpoint
If Phase 3 fails to confirm sustained weight loss or safety, the funding could be seen as a sunk cost with limited upside.
Key entities
- CompanyPfizer
U.S. pharmaceutical giant developing the obesity drug berobenatide.
- InvestorBlackstone Life Sciences
Private‑equity arm providing development funding for biotech projects.



